Development of an allogeneic adherent stem cell therapy for treatment of ischemic stroke

Robert W. Mays, Cesar V. Borlongan, Takao Yasuhara, Koichi Hara, Mina Maki, James E. Carroll, Robert J. Deans, David C. Hess

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

To determine the potential for using stem cells in the treatment of ischemic injuries of the central nervous system, clinically relevant experiments were performed administering human adult adherent bone marrow derived stem cells into a rat model of ischemic stroke. Variables such as the requirement for immunosuppression, route of cell administration, window for therapeutic benefit and optimal cell dosage have all been examined in a series of relevant translational experiments in animals undergoing middle cerebral artery ligation stroke injury. Animals were tested for improvements in locomotor and neurological function at time points as late as 6 months post-cell transplantation and demonstrated sustained statistically significant benefit from a single dose of cells. Following sacrifice, immunohistochemistry was performed on tissues to determine stem cell engraftment and fate, as well as neuroprotection of endogenous tissue at the sites of ischemic injury. The results indicate locomotor and neurological improvement correlates with improved neuroprotection and limited retention of the transplanted stem cells, with limited neuronal fate. The observed benefit occurs in a cell dosage dependent fashion suggesting a pharmacological role for the cells when administered intravenously in these injury models.

Original languageEnglish
Pages (from-to)34-46
Number of pages13
JournalJournal of Experimental Stroke and Translational Medicine
Volume3
Issue number1
Publication statusPublished - 2010
Externally publishedYes

Fingerprint

Cell- and Tissue-Based Therapy
Stem Cells
Stroke
Wounds and Injuries
Therapeutics
Middle Cerebral Artery Infarction
Cell Transplantation
Immunosuppression
Ligation
Central Nervous System
Bone Marrow
Immunohistochemistry
Pharmacology
Neuroprotection

Keywords

  • Ischemic stroke
  • Neuroprotection
  • Stem and progenitor cells
  • Translational research
  • Xenogeneic graft

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Clinical Neurology
  • Cognitive Neuroscience
  • Neurology

Cite this

Mays, R. W., Borlongan, C. V., Yasuhara, T., Hara, K., Maki, M., Carroll, J. E., ... Hess, D. C. (2010). Development of an allogeneic adherent stem cell therapy for treatment of ischemic stroke. Journal of Experimental Stroke and Translational Medicine, 3(1), 34-46.

Development of an allogeneic adherent stem cell therapy for treatment of ischemic stroke. / Mays, Robert W.; Borlongan, Cesar V.; Yasuhara, Takao; Hara, Koichi; Maki, Mina; Carroll, James E.; Deans, Robert J.; Hess, David C.

In: Journal of Experimental Stroke and Translational Medicine, Vol. 3, No. 1, 2010, p. 34-46.

Research output: Contribution to journalArticle

Mays, RW, Borlongan, CV, Yasuhara, T, Hara, K, Maki, M, Carroll, JE, Deans, RJ & Hess, DC 2010, 'Development of an allogeneic adherent stem cell therapy for treatment of ischemic stroke', Journal of Experimental Stroke and Translational Medicine, vol. 3, no. 1, pp. 34-46.
Mays, Robert W. ; Borlongan, Cesar V. ; Yasuhara, Takao ; Hara, Koichi ; Maki, Mina ; Carroll, James E. ; Deans, Robert J. ; Hess, David C. / Development of an allogeneic adherent stem cell therapy for treatment of ischemic stroke. In: Journal of Experimental Stroke and Translational Medicine. 2010 ; Vol. 3, No. 1. pp. 34-46.
@article{a31862d333ab42c0b3f3b732027e9a0a,
title = "Development of an allogeneic adherent stem cell therapy for treatment of ischemic stroke",
abstract = "To determine the potential for using stem cells in the treatment of ischemic injuries of the central nervous system, clinically relevant experiments were performed administering human adult adherent bone marrow derived stem cells into a rat model of ischemic stroke. Variables such as the requirement for immunosuppression, route of cell administration, window for therapeutic benefit and optimal cell dosage have all been examined in a series of relevant translational experiments in animals undergoing middle cerebral artery ligation stroke injury. Animals were tested for improvements in locomotor and neurological function at time points as late as 6 months post-cell transplantation and demonstrated sustained statistically significant benefit from a single dose of cells. Following sacrifice, immunohistochemistry was performed on tissues to determine stem cell engraftment and fate, as well as neuroprotection of endogenous tissue at the sites of ischemic injury. The results indicate locomotor and neurological improvement correlates with improved neuroprotection and limited retention of the transplanted stem cells, with limited neuronal fate. The observed benefit occurs in a cell dosage dependent fashion suggesting a pharmacological role for the cells when administered intravenously in these injury models.",
keywords = "Ischemic stroke, Neuroprotection, Stem and progenitor cells, Translational research, Xenogeneic graft",
author = "Mays, {Robert W.} and Borlongan, {Cesar V.} and Takao Yasuhara and Koichi Hara and Mina Maki and Carroll, {James E.} and Deans, {Robert J.} and Hess, {David C.}",
year = "2010",
language = "English",
volume = "3",
pages = "34--46",
journal = "Journal of Experimental Stroke and Translational Medicine",
issn = "1939-067X",
publisher = "Society for Experimental Stroke",
number = "1",

}

TY - JOUR

T1 - Development of an allogeneic adherent stem cell therapy for treatment of ischemic stroke

AU - Mays, Robert W.

AU - Borlongan, Cesar V.

AU - Yasuhara, Takao

AU - Hara, Koichi

AU - Maki, Mina

AU - Carroll, James E.

AU - Deans, Robert J.

AU - Hess, David C.

PY - 2010

Y1 - 2010

N2 - To determine the potential for using stem cells in the treatment of ischemic injuries of the central nervous system, clinically relevant experiments were performed administering human adult adherent bone marrow derived stem cells into a rat model of ischemic stroke. Variables such as the requirement for immunosuppression, route of cell administration, window for therapeutic benefit and optimal cell dosage have all been examined in a series of relevant translational experiments in animals undergoing middle cerebral artery ligation stroke injury. Animals were tested for improvements in locomotor and neurological function at time points as late as 6 months post-cell transplantation and demonstrated sustained statistically significant benefit from a single dose of cells. Following sacrifice, immunohistochemistry was performed on tissues to determine stem cell engraftment and fate, as well as neuroprotection of endogenous tissue at the sites of ischemic injury. The results indicate locomotor and neurological improvement correlates with improved neuroprotection and limited retention of the transplanted stem cells, with limited neuronal fate. The observed benefit occurs in a cell dosage dependent fashion suggesting a pharmacological role for the cells when administered intravenously in these injury models.

AB - To determine the potential for using stem cells in the treatment of ischemic injuries of the central nervous system, clinically relevant experiments were performed administering human adult adherent bone marrow derived stem cells into a rat model of ischemic stroke. Variables such as the requirement for immunosuppression, route of cell administration, window for therapeutic benefit and optimal cell dosage have all been examined in a series of relevant translational experiments in animals undergoing middle cerebral artery ligation stroke injury. Animals were tested for improvements in locomotor and neurological function at time points as late as 6 months post-cell transplantation and demonstrated sustained statistically significant benefit from a single dose of cells. Following sacrifice, immunohistochemistry was performed on tissues to determine stem cell engraftment and fate, as well as neuroprotection of endogenous tissue at the sites of ischemic injury. The results indicate locomotor and neurological improvement correlates with improved neuroprotection and limited retention of the transplanted stem cells, with limited neuronal fate. The observed benefit occurs in a cell dosage dependent fashion suggesting a pharmacological role for the cells when administered intravenously in these injury models.

KW - Ischemic stroke

KW - Neuroprotection

KW - Stem and progenitor cells

KW - Translational research

KW - Xenogeneic graft

UR - http://www.scopus.com/inward/record.url?scp=77953056863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953056863&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77953056863

VL - 3

SP - 34

EP - 46

JO - Journal of Experimental Stroke and Translational Medicine

JF - Journal of Experimental Stroke and Translational Medicine

SN - 1939-067X

IS - 1

ER -